Centanafadine

Centanafadine
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane;
CAS Number	924012-43-1;
PubChem CID	16095349;
ChemSpider	17253639;
UNII	D2A6T4UH9C;
KEGG	D10697 ;
CompTox Dashboard (EPA)	DTXSID201045788 ;
Chemical and physical data
Formula	C15H15N
Molar mass	209.292 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4;
	InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1; Key:HKHCSWPSUSWGLI-CABCVRRESA-N;

Centanafadine (INN; former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC₅₀ ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of 24 November 2025, Otsuka's pipeline indicates it is in phase II and III clinical trials for a number of different applications to medical conditions.

Pharmacology
Site	IC₅₀ (nM)	Action
SERTTooltip Serotonin transporter	83 nM	Antagonist
NETTooltip Norepinephrine transporter	6 nM	Antagonist
DATTooltip Dopamine transporter	38 nM	Antagonist